Literature DB >> 22979951

Pharmacological treatments in pathological gambling.

Jon E Grant1, Brian L Odlaug, Liana R N Schreiber.   

Abstract

Pathological gambling (PG) is a relatively common and often disabling psychiatric condition characterized by intrusive urges to engage in deleterious gambling behaviour. Although common and financially devastating to individuals and families, there currently exist no formally approved pharmacotherapeutic interventions for this disorder. This review seeks to examine the history of medication treatments for PG. A systematic review of the 18 double-blind, placebo-controlled pharmacotherapy studies conducted for the treatment of pathological gambling was conducted. Study outcome and the mean dose of medication administered was documented in an effort to determine a preferred medication choice in this population. A variety of medication classes have been examined in the treatment of PG with varying results. Antidepressants, atypical antipsychotics and mood stabilizers have demonstrated mixed results in controlled clinical trials. Although limited information is available, opioid antagonists and glutamatergic agents have demonstrated efficacious outcomes, especially for individuals with PG suffering from intense urges to engage in the behaviour. Given that several studies have demonstrated their efficacy in treating the symptoms associated with PG, opioid antagonists should be considered the first line treatment for PG at this time. Most published studies, however, have employed relatively small sample sizes, are of limited duration and involve possibly non-representative clinical groups (e.g. those without co-occurring psychiatric disorders). Response measures have varied across studies. Heterogeneity of PG treatment samples may also complicate identification of effective treatments. Identification of factors related to treatment response will help inform future studies and advance treatment strategies for PG.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Keywords:  addiction; gambling; impulsivity; pharmacology

Mesh:

Year:  2014        PMID: 22979951      PMCID: PMC4014021          DOI: 10.1111/j.1365-2125.2012.04457.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  47 in total

1.  12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.

Authors:  Pinhas N Dannon; Katherine Lowengrub; Ernest Musin; Yehudit Gonopolsky; Moshe Kotler
Journal:  J Clin Psychopharmacol       Date:  2007-12       Impact factor: 3.153

2.  Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.

Authors:  Jon E Grant; Suck Won Kim; Eric Hollander; Marc N Potenza
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

3.  Opioid antagonists in the treatment of impulse-control disorders.

Authors:  S W Kim
Journal:  J Clin Psychiatry       Date:  1998-04       Impact factor: 4.384

4.  Fluvoxamine in the treatment of compulsive buying.

Authors:  D W Black; P Monahan; J Gabel
Journal:  J Clin Psychiatry       Date:  1997-04       Impact factor: 4.384

5.  A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.

Authors:  E Hollander; C M DeCaria; J N Finkell; T Begaz; C M Wong; C Cartwright
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

6.  Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers.

Authors:  Martin Zack; Constantine X Poulos
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

7.  An empirical typology of lifetime and current gambling behaviors: association with health status of older adults.

Authors:  Song-Iee Hong; Paul Sacco; Renee M Cunningham-Williams
Journal:  Aging Ment Health       Date:  2009-03       Impact factor: 3.658

8.  A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling.

Authors:  Suck Won Kim; Jon E Grant; David E Adson; Young Chul Shin; Rocco Zaninelli
Journal:  J Clin Psychiatry       Date:  2002-06       Impact factor: 4.384

9.  N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.

Authors:  Jon E Grant; Suck Won Kim; Brian L Odlaug
Journal:  Biol Psychiatry       Date:  2007-04-18       Impact factor: 13.382

10.  Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

Authors:  Donald W Black; Stephan Arndt; William H Coryell; Tami Argo; Kelsie T Forbush; Martha C Shaw; Paul Perry; Jeff Allen
Journal:  J Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.153

View more
  22 in total

1.  Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Authors:  Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

2.  Drugs for addiction: a therapeutic area in need of a 'shot in the arm'.

Authors:  Andrea L Malizia; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Gambling disorder: an integrative review of animal and human studies.

Authors:  Katherine M Nautiyal; Mayumi Okuda; Rene Hen; Carlos Blanco
Journal:  Ann N Y Acad Sci       Date:  2017-04       Impact factor: 5.691

4.  Chronic administration of the dopamine D2/3 agonist ropinirole invigorates performance of a rodent slot machine task, potentially indicative of less distractible or compulsive-like gambling behaviour.

Authors:  Paul J Cocker; M Tremblay; S Kaur; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2016-10-06       Impact factor: 4.530

Review 5.  Pharmacological interventions for the treatment of disordered and problem gambling.

Authors:  Nicki Dowling; Stephanie Merkouris; Dan Lubman; Shane Thomas; Henrietta Bowden-Jones; Sean Cowlishaw
Journal:  Cochrane Database Syst Rev       Date:  2022-09-22

6.  Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial.

Authors:  Antonio Marcelo Cabrita de Brito; Moema Galindo de Almeida Pinto; Gabriel Bronstein; Elizabeth Carneiro; Daniela Faertes; Viviane Fukugawa; Angela Duque; Fatima Vasconcellos; Hermano Tavares
Journal:  J Gambl Stud       Date:  2017-03

Review 7.  Pharmacological treatments in gambling disorder: a qualitative review.

Authors:  Matteo Lupi; Giovanni Martinotti; Tiziano Acciavatti; Mauro Pettorruso; Marcella Brunetti; Rita Santacroce; Eduardo Cinosi; Giuseppe Di Iorio; Marco Di Nicola; Massimo Di Giannantonio
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

8.  Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.

Authors:  Inge Mick; Jim Myers; Anna C Ramos; Paul R A Stokes; David Erritzoe; Alessandro Colasanti; Roger N Gunn; Eugenii A Rabiner; Graham E Searle; Adam D Waldman; Mark C Parkin; Alan D Brailsford; José C F Galduróz; Henrietta Bowden-Jones; Luke Clark; David J Nutt; Anne R Lingford-Hughes
Journal:  Neuropsychopharmacology       Date:  2015-11-10       Impact factor: 7.853

9.  Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder.

Authors:  Patricia Di Ciano; Bernard Le Foll
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

10.  Pharmacotherapy and group cognitive behavioral therapy enhance follow-up treatment duration in gambling disorder patients.

Authors:  Sam-Wook Choi; Young-Chul Shin; HyunChul Youn; Se-Won Lim; Juwon Ha
Journal:  Ann Gen Psychiatry       Date:  2016-08-12       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.